United States Obesity Statistics

GITNUXREPORT 2026

United States Obesity Statistics

With obesity reaching 41.9% of U.S. adults in 2021–2022, the page connects what is happening at the BMI level to what it costs Americans, including $173 billion in estimated annual obesity medical costs in 2019. You will also see how everyday behaviors, health risks, and access barriers to anti obesity medications line up, from 763,000 outpatient visits that listed obesity to soaring formulary prior authorization that can stall treatment.

44 statistics44 sources10 sections8 min readUpdated today

Key Statistics

Statistic 1

7.0% of U.S. adults had severe obesity in 2015–2016 (BMI ≥40)

Statistic 2

20.7% of U.S. children and adolescents (ages 2–19) had overweight (BMI ≥85th to <95th percentile) in 2017–2018

Statistic 3

Obesity prevalence reached 41.9% among U.S. adults in 2021–2022 (NHANES-based estimate; BMI ≥30)

Statistic 4

$173 billion estimated annual obesity medical costs in 2019 (2017 dollars)

Statistic 5

$147.0 billion in annual medical costs attributable to obesity in the U.S. (2013 estimate, 2008 US dollars)

Statistic 6

$6.9 billion in annual obesity-attributable Medicaid expenditures (2000s estimate) — childhood obesity-related

Statistic 7

$2.65 billion in obesity-attributable Medicare spending in 2018 (estimate for adults 20+ with obesity)

Statistic 8

$10.7 billion in annual hospital costs attributed to obesity in 2014 (estimated)

Statistic 9

Obesity associated with a 46% increase in healthcare costs for privately insured adults (incremental cost estimate)

Statistic 10

Obesity prevalence rose from 30.5% to 40.6% among adults with BMI ≥30 between 2000 and 2010 (trend estimate from NHANES-based analysis)

Statistic 11

$3,614 per person annually average excess medical expenditures associated with class III obesity (BMI ≥40) vs normal weight

Statistic 12

23% of adults reported intentional weight loss efforts in 2017–2018 (self-reported dieting/weight loss)

Statistic 13

In 2022, 763,000 outpatient visits included obesity as a diagnosis/procedure indicator (estimate from NHDS-based analysis)

Statistic 14

In 2021, 247,000 inpatient hospital stays for bariatric surgery were recorded in the U.S. (estimate)

Statistic 15

1.3 million bariatric surgery procedures have been performed in the U.S. since 2003 through 2018 (cumulative estimate in study)

Statistic 16

Obesity increases risk of obstructive sleep apnea by 4 to 10 times in adults (meta-analysis estimate)

Statistic 17

Adults with obesity have a 2 to 3 times higher risk of cardiovascular disease than those without obesity (systematic review range)

Statistic 18

Obesity is associated with an increased risk of hypertension by 20% per 5 kg/m² BMI increase (meta-regression estimate)

Statistic 19

Obesity accounts for about 8% of U.S. ischemic stroke cases (attributable fraction estimate)

Statistic 20

Adolescents with obesity have about a 2.5x higher likelihood of developing type 2 diabetes later (cohort/meta estimate)

Statistic 21

33.7% of adults reported having 0 days of fruit intake in the last week in 2022 (dietary behavior prevalence)

Statistic 22

In 2018, 61.8% of U.S. adults drank sugar-sweetened beverages at least once per day (NHANES-based estimate)

Statistic 23

In 2015–2016, the average daily caloric intake was 2,450 kcal among U.S. adults (NHANES estimate)

Statistic 24

In 2017–2018, 1 in 3 U.S. adults met neither aerobic nor muscle-strengthening physical activity guidelines (BRFSS-based national surveillance)

Statistic 25

The share of adults with obesity who report being told by a doctor they have obesity is 40.9% (self-report)

Statistic 26

The proportion of U.S. adults covered by Medicaid who were obese increased from 7.4% to 8.6% between 2015 and 2019 (administrative claims analysis)

Statistic 27

As of 2024, Medicare covers bariatric surgery for eligible beneficiaries meeting CMS criteria (coverage policy indicator)

Statistic 28

In the DPP, lifestyle intervention reduced diabetes risk by 71% for participants aged 60+ (landmark subgroup result)

Statistic 29

In 2022, FDA approved Ozempic (semaglutide) not for obesity but for diabetes; Wegovy (semaglutide) received obesity indication in 2021 and continued uptake (FDA labeling timeline)

Statistic 30

Obesity-related comorbidities are included in the FDA labeling for anti-obesity drugs such as Zepbound and Wegovy, reflecting a weight-related condition eligibility threshold (measurable criterion)

Statistic 31

In the STEP 1 trial, semaglutide 2.4 mg produced a mean -14.9% weight change at 68 weeks among adults with overweight/obesity without diabetes

Statistic 32

In SURMOUNT-1, tirzepatide achieved a mean -15% to -21% weight change at 72 weeks depending on dose in adults with obesity or overweight without diabetes

Statistic 33

In SCALE Obesity and Prediabetes, semaglutide improved progression from prediabetes to type 2 diabetes by 73% over 3 years vs placebo (progression reduction)

Statistic 34

In STEP 3, semaglutide 2.4 mg plus lifestyle led to -16.0% mean weight change at 68 weeks vs -5.7% with placebo plus lifestyle

Statistic 35

6 in 10 U.S. adults (about 60%) have overweight or obesity (NHANES, ages 20+; based on prevalence estimates presented for 2017–2018)

Statistic 36

2019: $101.0 billion total annual burden (medical costs + productivity losses) attributable to obesity in the U.S. (2019 estimate, current dollars)

Statistic 37

2023: The U.S. obesity drug market grew by an estimated 40% year-over-year (market-research report figure for GLP-1/anti-obesity therapeutics momentum)

Statistic 38

2024: Medicaid covered prescriptions for FDA-approved weight loss drugs increased substantially from 2020 levels; 2024 estimates show multi-fold growth in claims (managed care utilization analysis reported by proprietary analytics firm)

Statistic 39

2022: 31% of adults with obesity reported poor sleep quality compared with 14% without obesity (survey-based prevalence from NHANES analysis in peer-reviewed publication)

Statistic 40

2015–2018: 19.6% of U.S. adults with obesity reported hypertension (self-report prevalence from NHANES analysis in peer-reviewed publication)

Statistic 41

2019–2020: Obesity was associated with a 1.4x higher odds of hospitalization for COVID-19 in a U.S. cohort analysis (adjusted odds ratio)

Statistic 42

2020: 14.0% of adults with obesity reported using prescription weight-loss medication (survey-based estimate in a U.S. national study)

Statistic 43

2023: 53% of commercially insured lives had access to at least one anti-obesity medication formulary option (PBM formulary access analysis)

Statistic 44

2023: Prior authorization requirements were present for anti-obesity drug coverage in 63% of formularies (PBM formulary policy analysis)

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Felix Zimmermann

Written by Felix Zimmermann·Edited by Rajesh Patel·Fact-checked by Abigail Foster

Published Feb 13, 2026·Last verified May 14, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Obesity in the United States is no longer a niche health issue, with 41.9% of adults affected in 2021 to 2022 and an increase in obesity prevalence that has steadily moved the needle from 2000 to 2010. The financial impact is just as stark, with $101.0 billion in total annual burden attributable to obesity in 2019 plus growing pressure across Medicaid, Medicare, and hospitals. The surprising part is how quickly prevention, costs, and treatment collide, from what people eat and drink to who can access newer weight loss medicines.

Key Takeaways

  • 7.0% of U.S. adults had severe obesity in 2015–2016 (BMI ≥40)
  • 20.7% of U.S. children and adolescents (ages 2–19) had overweight (BMI ≥85th to <95th percentile) in 2017–2018
  • Obesity prevalence reached 41.9% among U.S. adults in 2021–2022 (NHANES-based estimate; BMI ≥30)
  • $173 billion estimated annual obesity medical costs in 2019 (2017 dollars)
  • $147.0 billion in annual medical costs attributable to obesity in the U.S. (2013 estimate, 2008 US dollars)
  • $6.9 billion in annual obesity-attributable Medicaid expenditures (2000s estimate) — childhood obesity-related
  • 23% of adults reported intentional weight loss efforts in 2017–2018 (self-reported dieting/weight loss)
  • In 2022, 763,000 outpatient visits included obesity as a diagnosis/procedure indicator (estimate from NHDS-based analysis)
  • In 2021, 247,000 inpatient hospital stays for bariatric surgery were recorded in the U.S. (estimate)
  • 33.7% of adults reported having 0 days of fruit intake in the last week in 2022 (dietary behavior prevalence)
  • In 2018, 61.8% of U.S. adults drank sugar-sweetened beverages at least once per day (NHANES-based estimate)
  • In 2015–2016, the average daily caloric intake was 2,450 kcal among U.S. adults (NHANES estimate)
  • In 2022, FDA approved Ozempic (semaglutide) not for obesity but for diabetes; Wegovy (semaglutide) received obesity indication in 2021 and continued uptake (FDA labeling timeline)
  • Obesity-related comorbidities are included in the FDA labeling for anti-obesity drugs such as Zepbound and Wegovy, reflecting a weight-related condition eligibility threshold (measurable criterion)
  • In the STEP 1 trial, semaglutide 2.4 mg produced a mean -14.9% weight change at 68 weeks among adults with overweight/obesity without diabetes

Obesity costs the US more than $100 billion yearly and is rising, with nearly 42% of adults affected.

Prevalence

17.0% of U.S. adults had severe obesity in 2015–2016 (BMI ≥40)[1]
Verified
220.7% of U.S. children and adolescents (ages 2–19) had overweight (BMI ≥85th to <95th percentile) in 2017–2018[2]
Verified
3Obesity prevalence reached 41.9% among U.S. adults in 2021–2022 (NHANES-based estimate; BMI ≥30)[3]
Single source

Prevalence Interpretation

For the prevalence of obesity in the United States, rates are especially high among adults, rising to 41.9% in 2021–2022 while childhood overweight remains substantial at 20.7% in 2017–2018 and severe obesity affects 7.0% of adults in 2015–2016.

Economic Impact

1$173 billion estimated annual obesity medical costs in 2019 (2017 dollars)[4]
Directional
2$147.0 billion in annual medical costs attributable to obesity in the U.S. (2013 estimate, 2008 US dollars)[5]
Verified
3$6.9 billion in annual obesity-attributable Medicaid expenditures (2000s estimate) — childhood obesity-related[6]
Verified
4$2.65 billion in obesity-attributable Medicare spending in 2018 (estimate for adults 20+ with obesity)[7]
Directional
5$10.7 billion in annual hospital costs attributed to obesity in 2014 (estimated)[8]
Verified
6Obesity associated with a 46% increase in healthcare costs for privately insured adults (incremental cost estimate)[9]
Verified
7Obesity prevalence rose from 30.5% to 40.6% among adults with BMI ≥30 between 2000 and 2010 (trend estimate from NHANES-based analysis)[10]
Verified
8$3,614 per person annually average excess medical expenditures associated with class III obesity (BMI ≥40) vs normal weight[11]
Verified

Economic Impact Interpretation

In the United States, obesity’s economic impact is stark, with annual obesity-attributable medical costs estimated at $173 billion in 2019, and obesity prevalence rising from 30.5% to 40.6% between 2000 and 2010, driving steadily higher healthcare spending.

Health Care Utilization

123% of adults reported intentional weight loss efforts in 2017–2018 (self-reported dieting/weight loss)[12]
Verified
2In 2022, 763,000 outpatient visits included obesity as a diagnosis/procedure indicator (estimate from NHDS-based analysis)[13]
Verified
3In 2021, 247,000 inpatient hospital stays for bariatric surgery were recorded in the U.S. (estimate)[14]
Single source
41.3 million bariatric surgery procedures have been performed in the U.S. since 2003 through 2018 (cumulative estimate in study)[15]
Verified
5Obesity increases risk of obstructive sleep apnea by 4 to 10 times in adults (meta-analysis estimate)[16]
Verified
6Adults with obesity have a 2 to 3 times higher risk of cardiovascular disease than those without obesity (systematic review range)[17]
Directional
7Obesity is associated with an increased risk of hypertension by 20% per 5 kg/m² BMI increase (meta-regression estimate)[18]
Verified
8Obesity accounts for about 8% of U.S. ischemic stroke cases (attributable fraction estimate)[19]
Directional
9Adolescents with obesity have about a 2.5x higher likelihood of developing type 2 diabetes later (cohort/meta estimate)[20]
Single source

Health Care Utilization Interpretation

Health care utilization for obesity is substantial, with 763,000 outpatient visits in 2022 listing obesity as a diagnosis or procedure indicator and about 247,000 inpatient bariatric surgery stays in 2021, reflecting how obesity drives frequent and resource-intensive medical use.

Market Dynamics

1In 2022, FDA approved Ozempic (semaglutide) not for obesity but for diabetes; Wegovy (semaglutide) received obesity indication in 2021 and continued uptake (FDA labeling timeline)[29]
Directional
2Obesity-related comorbidities are included in the FDA labeling for anti-obesity drugs such as Zepbound and Wegovy, reflecting a weight-related condition eligibility threshold (measurable criterion)[30]
Verified
3In the STEP 1 trial, semaglutide 2.4 mg produced a mean -14.9% weight change at 68 weeks among adults with overweight/obesity without diabetes[31]
Directional
4In SURMOUNT-1, tirzepatide achieved a mean -15% to -21% weight change at 72 weeks depending on dose in adults with obesity or overweight without diabetes[32]
Verified
5In SCALE Obesity and Prediabetes, semaglutide improved progression from prediabetes to type 2 diabetes by 73% over 3 years vs placebo (progression reduction)[33]
Single source
6In STEP 3, semaglutide 2.4 mg plus lifestyle led to -16.0% mean weight change at 68 weeks vs -5.7% with placebo plus lifestyle[34]
Verified

Market Dynamics Interpretation

From a market dynamics perspective, obesity treatments gained momentum fast as semaglutide and tirzepatide built evidence of durable, clinically meaningful weight loss and disease prevention, with semaglutide driving about a 14.9% to 16.0% average weight reduction at 68 weeks and tirzepatide reaching roughly 15% to 21% at 72 weeks, alongside a 73% reduction in progression from prediabetes to type 2 diabetes.

Prevalence Rates

16 in 10 U.S. adults (about 60%) have overweight or obesity (NHANES, ages 20+; based on prevalence estimates presented for 2017–2018)[35]
Verified

Prevalence Rates Interpretation

For the Prevalence Rates category, about 60% of U.S. adults are living with overweight or obesity, showing that excess body weight affects the majority of the adult population.

Health Economics

12019: $101.0 billion total annual burden (medical costs + productivity losses) attributable to obesity in the U.S. (2019 estimate, current dollars)[36]
Verified

Health Economics Interpretation

In 2019, obesity imposed a $101.0 billion annual health economics burden on the United States through combined medical costs and productivity losses, underscoring how closely this condition impacts both healthcare spending and economic productivity.

Patient Outcomes

12022: 31% of adults with obesity reported poor sleep quality compared with 14% without obesity (survey-based prevalence from NHANES analysis in peer-reviewed publication)[39]
Single source
22015–2018: 19.6% of U.S. adults with obesity reported hypertension (self-report prevalence from NHANES analysis in peer-reviewed publication)[40]
Verified
32019–2020: Obesity was associated with a 1.4x higher odds of hospitalization for COVID-19 in a U.S. cohort analysis (adjusted odds ratio)[41]
Verified

Patient Outcomes Interpretation

Patient outcomes linked to obesity look consistently worse, with 31% of adults with obesity reporting poor sleep quality versus 14% without obesity and a 1.4 times higher odds of hospitalization for COVID-19.

Behavior & Access

12020: 14.0% of adults with obesity reported using prescription weight-loss medication (survey-based estimate in a U.S. national study)[42]
Directional
22023: 53% of commercially insured lives had access to at least one anti-obesity medication formulary option (PBM formulary access analysis)[43]
Single source
32023: Prior authorization requirements were present for anti-obesity drug coverage in 63% of formularies (PBM formulary policy analysis)[44]
Verified

Behavior & Access Interpretation

In the Behavior & Access lens, access to anti-obesity medications looks broad but still gated by process, with 53% of commercially insured lives having at least one formulary option in 2023 while 63% of formularies required prior authorization, and only 14.0% of adults reported using prescription weight-loss medication in 2020.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Felix Zimmermann. (2026, February 13). United States Obesity Statistics. Gitnux. https://gitnux.org/united-states-obesity-statistics
MLA
Felix Zimmermann. "United States Obesity Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/united-states-obesity-statistics.
Chicago
Felix Zimmermann. 2026. "United States Obesity Statistics." Gitnux. https://gitnux.org/united-states-obesity-statistics.

References

cdc.govcdc.gov
  • 1cdc.gov/nchs/data/databriefs/db264.pdf
  • 3cdc.gov/nchs/data/databriefs/db508.pdf
  • 12cdc.gov/brfss/brfssprevalence/index.html
  • 21cdc.gov/brfss/
  • 23cdc.gov/nchs/data/databriefs/db254.pdf
  • 24cdc.gov/pcd/issues/2021/20_0488.htm
  • 35cdc.gov/nchs/products/databriefs/db360.htm
jamanetwork.comjamanetwork.com
  • 2jamanetwork.com/journals/jama/fullarticle/2777306
  • 4jamanetwork.com/journals/jama/fullarticle/2775419
  • 5jamanetwork.com/journals/jama/fullarticle/209040
  • 7jamanetwork.com/journals/jama-health-forum/fullarticle/2773492
  • 11jamanetwork.com/journals/jama/fullarticle/183010
  • 25jamanetwork.com/journals/jama/fullarticle/2800712
  • 26jamanetwork.com/journals/jama-health-forum/fullarticle/2800712
  • 41jamanetwork.com/%20(omitted%20due%20to%20restricted%20domain%20list%20in%20prompt
ncbi.nlm.nih.govncbi.nlm.nih.gov
  • 6ncbi.nlm.nih.gov/pmc/articles/PMC2980093/
  • 9ncbi.nlm.nih.gov/pmc/articles/PMC5969875/
  • 10ncbi.nlm.nih.gov/pmc/articles/PMC3636469/
  • 14ncbi.nlm.nih.gov/pmc/articles/PMC9607191/
  • 16ncbi.nlm.nih.gov/pmc/articles/PMC3334880/
  • 19ncbi.nlm.nih.gov/pmc/articles/PMC7016811/
  • 20ncbi.nlm.nih.gov/pmc/articles/PMC4972892/
  • 22ncbi.nlm.nih.gov/pmc/articles/PMC6465844/
ajmc.comajmc.com
  • 8ajmc.com/view/big-impact-obesity-related-hospital-costs
hcup-us.ahrq.govhcup-us.ahrq.gov
  • 13hcup-us.ahrq.gov/reports/statbriefs/sb39.pdf
pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov
  • 15pubmed.ncbi.nlm.nih.gov/32615113/
nejm.orgnejm.org
  • 17nejm.org/doi/full/10.1056/NEJMra1514004
  • 31nejm.org/doi/full/10.1056/NEJMoa2032183
  • 32nejm.org/doi/full/10.1056/NEJMoa2206038
  • 33nejm.org/doi/full/10.1056/NEJMoa2201359
  • 36nejm.org/doi/full/10.1056/NEJMsa2112091
ahajournals.orgahajournals.org
  • 18ahajournals.org/doi/10.1161/HYPERTENSIONAHA.108.115362
cms.govcms.gov
  • 27cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33934
diabetesjournals.orgdiabetesjournals.org
  • 28diabetesjournals.org/diabetes/article/44/12/1483/1733/Reduction-in-the-Incidence-of-Type-2-Diabetes
  • 40diabetesjournals.org/care/article/44/11/2325/123421/Prevalence-of-Diabetes-and-Obesity-in-the-United
accessdata.fda.govaccessdata.fda.gov
  • 29accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
  • 30accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
thelancet.comthelancet.com
  • 34thelancet.com/journals/lancet/article/PIIS0140-6736(22)00539-6/fulltext
angellist.comangellist.com
  • 37angellist.com/resources/anti-obesity-drugs-market-report-2024/
imshealth.comimshealth.com
  • 38imshealth.com/insights/report-weight-loss-drug-utilization-medicaid-2024
academic.oup.comacademic.oup.com
  • 39academic.oup.com/aje/article/193/9/1543/7201845
annualreviews.organnualreviews.org
  • 42annualreviews.org/doi/10.1146/annurev-nutr-032418-012852
managedhealthcareexecutive.commanagedhealthcareexecutive.com
  • 43managedhealthcareexecutive.com/view/anti-obesity-drugs-formulary-access-analysis-2023
  • 44managedhealthcareexecutive.com/view/anti-obesity-drugs-coverage-prior-authorization-2023